Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.750 +0.020 (+0.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

September 25, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

1 Gene Editing Stock to Buy Now, and 1 to Sell ↗

September 23, 2023

Target markets matter. So does having the cash to get to them.

Via The Motley Fool

Editas Medicine Announces Upcoming Investor Events

August 30, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Analyst Expectations for Editas Medicine's Future ↗

August 29, 2023

Via Benzinga

Expert Ratings for Editas Medicine ↗

August 03, 2023

Via Benzinga

Is Editas Medicine Stock a Buy Now? ↗

June 28, 2023

The fortunes of this once-promising biotech company have changed in the past year.

Via The Motley Fool

These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street ↗

August 23, 2023

Is the Street's optimism justified here?

Via The Motley Fool

Editas Medicine Announces Second Quarter 2023 Results and Business Updates

August 02, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization

July 27, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

What 6 Analyst Ratings Have To Say About Editas Medicine ↗

June 13, 2023

Via Benzinga

Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update

July 26, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

July 24, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

This 1 Problem Could Sink at Least 4 Gene-Editing Stocks ↗

June 29, 2023

Reaching profitability could be harder than investors expect.

Via The Motley Fool

What Is CRISPR And Why Should Your Portfolio Care? ↗

June 25, 2023

CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player.

Via Talk Markets

After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock? ↗

June 20, 2023

It's not about to start making money anytime soon.

Via The Motley Fool

Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 15, 2023

Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.

Via Benzinga

2 Short-Squeeze Candidates That Could Go Parabolic ↗

June 15, 2023

Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.

Via The Motley Fool

Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 15, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Editas Medicine Announces Pricing of Offering of Common Stock

June 14, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces Offering of Common Stock

June 14, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023 ↗

June 13, 2023

Via Benzinga

5 Stocks to Buy With Explosive 500% Potential ↗

June 12, 2023

Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential.

Via InvestorPlace

Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders ↗

June 09, 2023

Editas Medicine Inc (NASDAQ: EDIT) annou

Via Benzinga

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

June 09, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today? ↗

June 06, 2023

Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector.

Via InvestorPlace

Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia

June 06, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial ↗

June 01, 2023

A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that...

Via Benzinga

7 Short-Squeeze Stocks Set for a May Rally ↗

May 22, 2023

While targeting the best short-squeeze stocks to buy now can be incredibly treacherous, they may also yield robust returns.

Via InvestorPlace

Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You? ↗

May 21, 2023

It's facing a few issues that are practically guaranteed to affect shareholder returns.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.